Valuation: Viking Therapeutics, Inc.

Market Cap 4.04B 3.55B 3.3B 3.03B 5.69B 389B 5.78B 39.18B 15.31B 191B 15.16B 14.84B 661B P/E 2026 *
-7.24x
P/E 2027 * -7.52x
Enterprise Value 3.59B 3.15B 2.93B 2.69B 5.05B 346B 5.13B 34.81B 13.6B 170B 13.47B 13.18B 587B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.21%
Yield 2026 *
-
Yield 2027 * -
1 day-1.70%
1 week-6.18%
Current month-10.82%
1 month-8.13%
3 months+6.23%
6 months+7.98%
Current year-1.11%
1 week 34.39
Extreme 34.39
38.16
1 month 34.39
Extreme 34.39
42.79
Current year 25.77
Extreme 25.77
42.79
1 year 22.96
Extreme 22.959
43.15
3 years 8.28
Extreme 8.28
99.41
5 years 2.02
Extreme 2.02
99.41
10 years 0.88
Extreme 0.88
99.41
Manager TitleAgeSince
Chief Executive Officer 60 2012-09-23
Director of Finance/CFO 55 2021-01-03
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 68 2015-04-30
Chairman 60 2012-09-23
Director/Board Member 53 2014-04-30
Date Insider Type Main position Quantity % Market Cap.
6/1/26 Free

Chief Technology Officer

190,000 0.1636%
3/10/26 Buy

Executive/Senior Manager

4,475 0.0039%
1/12/26 Free

Executive/Senior Manager

180,000 0.1592%
Change 5-day change 1-year change 3-year change Capi.($)
-1.70%-6.18%+3.85%+139.77% 4.04B
+0.93%+6.97%+62.83%+67.97% 57.28B
-1.92%+6.03%+43.68%+84.56% 54.99B
-0.46%-1.29%+3.28%+422.58% 23.18B
-2.97%-2.35%-22.03%-16.54% 22.59B
-0.36%+5.73%+30.99%-3.58% 20.46B
-1.34%+0.51%+25.02%-30.27% 17.56B
-1.44%+5.67%+32.54%+544.11% 15.67B
-1.30%-5.02%+165.62%+291.37% 14.46B
-0.50%-0.98%+23.62%+178.38% 13.92B
Average -1.11%+0.53%+36.94%+167.83% 24.41B
Weighted average by Cap. -0.89%+1.96%+40.56%+135.75%

Financials

2026 *2027 *
Net sales - -
Net income -563M -494M -460M -422M -793M -54.22B -805M -5.46B -2.13B -26.65B -2.11B -2.07B -92.16B -587M -516M -480M -440M -827M -56.57B -840M -5.7B -2.23B -27.81B -2.21B -2.16B -96.16B
Net Debt -450M -396M -368M -338M -634M -43.37B -644M -4.37B -1.71B -21.32B -1.69B -1.65B -73.73B -523M -460M -428M -392M -737M -50.41B -749M -5.08B -1.98B -24.78B -1.97B -1.92B -85.69B
Logo Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Employees
59
Date Price Change Volume
26-07-24 US$34.79 -1.70% 1,838,073
26-07-23 US$35.39 -5.15% 3,246,306
26-07-22 US$37.31 -1.69% 1,347,832
26-07-21 US$37.95 +4.32% 1,790,970
26-07-20 US$36.38 -1.89% 1,911,409
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
34.79USD
Average target price
92.58USD
Spread / Average Target
+166.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VKTX Stock